WindMIL Therapeutics Appoints Dr. Kimberly Noonan as Executive Vice President, Chief Science & Technology Officer

WindMIL Therapeutics appointed Co-Founder Kimberly Noonan, to Executive Vice President, Chief Science & Technology Officer. In this role, her leadership will expand to include WindMIL’s efforts in manufacturing science and technology (MS&T) and leading the company’s work in gene-modified MILs (GM-MILs). 

WindMIL Therapeutics is a privately held clinical state oncology cell therapy company based in Baltimore, Maryland that leverages its proprietary platform to develop a novel class of cell therapies called MILs(Marrow Infiltrating Lymphocytes) derived from memory T cells found in the bone marrow.